{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:35Z","timestamp":1792790495519,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010376","name":"American Association of Clinical Endocrinologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013014","name":"Barrow Neurological Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.eprac.2022.04.010","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T21:22:46Z","timestamp":1650921766000},"page":"719-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach"],"prefix":"10.1016","volume":"28","author":[{"given":"Kevin C.J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidar R.","family":"Gosmanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Jasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Fecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ando.2018.07.001","article-title":"Introduction to expert opinion on endocrine complications of new anticancer therapies","volume":"79","author":"Castinetti","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.eprac.2022.04.010_bib4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.eprac.2022.04.010_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.010_bib6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.010_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11102-019-00978-4","article-title":"Ipilimumab-induced hypophysitis, a single academic center experience","volume":"22","author":"Snyders","year":"2019","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.eprac.2022.04.010_bib12","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"19","key":"10.1016\/j.eprac.2022.04.010_bib18","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib21","doi-asserted-by":"crossref","first-page":"101276","DOI":"10.1016\/j.beem.2019.04.010","article-title":"New causes of hypophysitis","volume":"33","author":"Yuen","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"230","key":"10.1016\/j.eprac.2022.04.010_bib22","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib23","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte\u2013associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.eprac.2022.04.010_bib24","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11102-018-0866-6","article-title":"Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis","volume":"21","author":"De Sousa","year":"2018","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports","volume":"47","author":"Marlier","year":"2014","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.010_bib31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/imj.12819","article-title":"Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series","volume":"45","author":"Lam","year":"2015","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14349","article-title":"Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy","volume":"94","author":"Yamauchi","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J\u00a0Med Case Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ando.2020.11.010","article-title":"Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: prevalence and etiology","volume":"82","author":"Ducloux","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib36","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib37","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.eprac.2022.04.010_bib40","doi-asserted-by":"crossref","first-page":"582394","DOI":"10.3389\/fonc.2020.582394","article-title":"Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review","volume":"10","author":"Barnabei","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib41","article-title":"Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis","volume":"2021","author":"Fosci","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib43","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","volume":"2018","author":"Gunawan","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.eprac.2022.04.010_bib44","doi-asserted-by":"crossref","first-page":"106427","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"36","key":"10.1016\/j.eprac.2022.04.010_bib45","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib47","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1210\/clinem\/dgaa133","article-title":"Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery","volume":"105","author":"Prete","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib50","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib52","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib53","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses","volume":"169","author":"Torino","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.010_bib54","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eprac.2022.04.010_bib56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib57","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Presse Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2022.04.010_bib59","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib61","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib62","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib63","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.04.010_bib64","first-page":"2087525","article-title":"Treatment of ipilimumab induced Graves\u2019 disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib65","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.04.010_bib67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/14737140.2019.1562342","article-title":"Management of immune-related adverse events resulting from immune checkpoint blockade","volume":"19","author":"Baroudjian","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"suppl 4","key":"10.1016\/j.eprac.2022.04.010_bib68","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib69","first-page":"1","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib70","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib71","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eprac.2022.04.010_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214603","article-title":"A\u00a0rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib73","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","article-title":"Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome","volume":"7","author":"Perdigoto","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.04.010_bib75","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.010_bib76","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib77","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00592-019-01402-w","article-title":"The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib78","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib79","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.2337\/dc20-0459","article-title":"Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019","volume":"43","author":"Liu","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.010_bib80","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.04.010_bib81","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dme.13762","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges","volume":"35","author":"Galligan","year":"2018","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.04.010_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01435-y","article-title":"Patient-centered diabetes care of cancer patients","volume":"21","author":"Kotwal","year":"2021","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.eprac.2022.04.010_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib84","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","author":"Smati","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib85","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.010_bib86","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.eprac.2022.04.010_bib87","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib89","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"11","key":"10.1016\/j.eprac.2022.04.010_bib90","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eprac.2022.04.010_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-induced endocrinopathies: assessment, management and monitoring","volume":"10","author":"Nogueira","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.04.010_bib92","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJM198908243210802","article-title":"Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism","volume":"321","author":"Oelkers","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.04.010_bib93","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.04.010_bib94","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib96","doi-asserted-by":"crossref","first-page":"bvab022","DOI":"10.1210\/jendso\/bvab022","article-title":"New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays","volume":"5","author":"Javorsky","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib97","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000507652","article-title":"Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature","volume":"13","author":"Salinas","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib98","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.04.010_bib99","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib100","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib101","first-page":"1","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib102","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.mayocpiqo.2020.07.006","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib103","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/CMR.0000000000000405","article-title":"Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination","volume":"27","author":"Lupu","year":"2017","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-021-00693-x","article-title":"Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use-case report and review of literature","volume":"21","author":"Newman","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib105","first-page":"1","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib106","first-page":"49","article-title":"Management of acute pancreatitis associated with checkpoint inhibitors","volume":"11","author":"Rogers","year":"2020","journal-title":"J\u00a0Adv Pract Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.04.010_bib107","first-page":"e40","article-title":"A\u00a0case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res"},{"issue":"10","key":"10.1016\/j.eprac.2022.04.010_bib109","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib110","first-page":"443","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.eprac.2022.04.010_bib111","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2022.04.010_bib112","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.eprac.2022.04.010_bib113","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol"},{"issue":"28","key":"10.1016\/j.eprac.2022.04.010_bib114","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2022.04.010_bib115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2200489X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2200489X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:13:12Z","timestamp":1761516792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2200489X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":114,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1530891X2200489X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.04.010","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}